The impact of Strituvad project presented at the annual TBVI meeting
Updated: Feb 27, 2020
Scientist and academics working in the STriTuVaD consortium participated to the TBVI meeting “Accelerating the TB vaccine pipeline – towards Horizon Europe” held from 27th to 29th January 2020 in Les Diablerets, Switzerland.
The occasion brought together 120 scientists and policy makers from 70 research institutes, universities, industries, funding agencies, technical agencies from 21 countries, and represented the opportunity to hear from key global stakeholders about their current activities in the field of tuberculosis vaccine R&D.
The three-days meeting was articulated into different sessions, each of them focusing on very specific aspects of the TB vaccine development pipeline.
In the first session “Progress in TB vaccine clinical product development”, our clinical partners Pere-Joan Cardona from Archivel Farma and Rhea Coler from IDRI presented the newest updates respectively on the RUTI and the ID93 vaccines.
“Our latest achievement – explain Olga Rué Clarós, CEO of Archivel Farma – regards the permission to proceed through a phase IIb clinical trials that we received last 20th of January. The clinical trials will take place at the indian partner All India Institute of Medical Sciences facilities in New Delhi and at the Department of Microbiology of the Agartala Government Medical College in Tripura”.
The data obtained from the clinical trials will be then compared with the data predicted with the simulations on virtual patients by the Universal Immune System Simulator (UISS), developed by the group from the University of Catania.
Prof Francesco Pappalardo from Catania talked about this aspect in the session “Innovation in vaccine technologies and modelling”, where he illustrated how the simulation platform will be able to simulate the immune system, the interaction with the TB disease, and the artificial immunity induced by vaccinations and treatments.
“At the moment, we implemented all the features needed to reproduce the immune system response induced by vaccines – explains Prof Pappalardo – and the platform has been now released to our clinical partners for evaluation and feedback gathering.”
The symposium closed with final remarks on the current situation and the future trajectories of TB vaccine research, with a view on the priorities for Horizon Europe programme.